Top Markets
#1 Zora Zora +31.06%
#2 Tutorial Tutorial +29.43%
#3 Fabric Protocol Fabric Protocol +25.51%
#4 Wrapped STX (Velar) Wrapped STX (Velar) +25.39%
#5 GALA GALA +25.12%
#6 Pieverse Pieverse +23.14%
#7 HashKey Platform Token HashKey Platform Token +22.61%
#8 EXOD EXOD +22.08%
#9 Derive Derive +21.57%
#10 Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash +21.33%
Coin of the day
Zora Zora
Settings
Language
ENGLISH
Currency
USD
Theme
Xspray Pharma AB (publ) Xspray Pharma AB (publ)

Xspray Pharma AB (publ)

XSPRAY
Rank in Stocks #24929
Xspray Pharma AB (publ), a pharmaceutical firm based in Solna, Sweden,... Xspray Pharma AB (publ), a pharmaceutical firm based in Solna, Sweden, specializes in developing protein kinase inhibitors for precise cancer treatments. Their current drug pipeline includes HyNap-Nilo, aimed at chronic myeloid leukemia; HyNap-Sora, which targets renal, liver, and several types of thyroid cancer; and HyNap-Dasa, intended for both chronic myeloid leukemia and acute lymphoblastic leukemia. Established in 2003, the company was formerly known as Xspray Microparticles AB until its name change to Xspray Pharma AB (publ) in 2017.
Share Price
$1.18
Market Cap
$55.82M
Change (1 day)
1.35%
Change (1 year)
-73.35%
Country
SE
Trade Xspray Pharma AB (publ) (XSPRAY)

Category

Healthcare
Revenue for Xspray Pharma AB (publ) (XSPRAY)
Revenue in Aug 2026 TTM: 0
According to Xspray Pharma AB (publ) latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Xspray Pharma AB (publ) from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH